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tThe natural history of HIV infection is similar to that of
other lentiviruses in that the virus causes life-long infec-
tion irrespective of whether infected individuals ever
develop disease. This is probably a function of the ability
of the reversely transcribed RNA of the virus to integrate
into the genome of cells of the immune system of the
host and persist indefinitely. Thus, there is no cohort of
individuals who develop curative immunity and resis-
tance to disease and whose immunity could therefore be
used as the guide for development and assessment of
efficacy of vaccines. Nevertheless, there are some HIV-
infected persons who remain clinically well for several
years despite persistent infection. Unlike acutely in-
fected individuals who develop extremely high titers of
virus and viral RNA in plasma, and who then lose CD41
T cells and then develop the well-known profound im-
munosuppression caused by the virus, the chronically
infected persons who remain healthy have very low virus
burdens, normal counts of CD41 T cells, and strong
long-lasting humoral and cellular immune responses to
the virus (Pantaleo and Fauci, 1995). If this state were the
best that can be found in nature, then this would be the
least that vaccinologists could aspire for in the quest to
develop control over HIV disease.
Because of the extremely variable disease pattern
caused by the virus (unpredictable onset of disease
following exposure to the virus, variations in the duration
of disease from acute to chronic protracted courses, and
the usually fatal outcome of disease), considerable em-
phasis has been placed on using macaque models of
HIV infection and disease. Two currently used models
are those caused by simian immunodeficiency virus (SIV)
and the chimeric SIV/HIV viruses that have the gag and
pol structural genes of SIV and the env of HIV-1
(Nathanson et al., 1999). Strains of both viruses are1 To whom correspondence and reprint requests should be ad-
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1highly pathogenic and cause the same type of severe
immunosuppression caused by HIV. Similar to HIV-in-
fected human beings, affected animals then become
high risks for development of life-threatening infections
by opportunistic pathogens (OI) and tumors.
We chose to conduct studies on pathogenesis and
vaccine development/assessment using the SHIV model
of HIV infection/disease because, unlike SIV which is
only an analog of HIV-1, SHIV has the env, tat, rev, and
vpu of HIV-1 and is therefore believed to be a more
relevant model of HIV-1. Our pathogenic strain of this
virus, SHIVKU, was developed by sequential passage of
SHIV-4, whose DNA was constructed and provided to us
by Dr. J. Sodroski, Harvard Medical School (Boston, MA)
in young macaques (Joag et al., 1996, 1998). SHIV-4 is
infectious but nonpathogenic in these animals, but after
four blind passages, the virus became highly pathogenic.
Infected animals developed very high virus burdens (ap-
proximately 108 copies of viral RNA in plasma), acute and
evere loss of CD41 T cells, minimal development of
mmune responses, severe immunosuppression, and fa-
al OIs, often within 6 months (Joag et al., 1996). More-
ver, SHIVKU caused disease after inoculation on the
ucosal surface of the vagina (Joag et al., 1998) and
ectum (Kumar et al., unpublished results) of macaques,
hus simulating sexually transmitted HIV disease. Ge-
etic clues of markers of the newly acquired virulence of
he virus were that two regulatory genes, vpu (unique to
IV-1 and not found in any SIVs) and nef, and the struc-
ural env gene of SHIV-4 had all undergone significant
utations (Stephens et al., 1996; McCormick-Davis et al.,
1998). Phenotypically, SHIVKU has a high tropism for
CD41 T cells and macrophages (Fig. 1), unlike SHIV-4
hat is strictly CD41 T-cell-tropic.
Having established an efficient challenge virus sys-
tem, we next sought to investigate whether a vaccine
against this virus could either prevent infection with the
challenge virus or slow its pathogenesis. Our first choice
was gp120, the hydrophilic portion of the envelope of
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2 MINIREVIEWHIV-1. Eight macaques were given a course of three
injections of 100, 50, and 50 mg of the protein, 3 and 7
weeks apart, the first being emulsified in Freund’s com-
plete adjuvant and the second and third in incomplete
Freund’s adjuvant. The animals were challenged 12
weeks following the third immunization. Close monitor-
ing of the immune responses during the immunization
process showed that all eight animals developed high
titers of binding antibodies to gp120, but none developed
neutralizing antibodies to the virus. Each injection of
antigen induced a transient gp120-specific CD41 T cell
response. None of the animals developed CTLs against
the virus. This CTL test utilized two types of targets,
herpesvirus saimiri-transformed CD41 T cells that were
noculated with infectious vaccine and challenge viruses
Kumar et al., 1999) and herpesvirus-transformed B cells
hat were inoculated with recombinant vaccinia virus
xpressing proteins of the virus. Following challenge, the
ight immunized macaques developed just as high virus
urdens as the four unvaccinated control macaques (Ku-
ar et al., 2000). These results confirmed concerns that
his vaccine would not elicit any protective immune re-
ponses against the virus.
Although the gp120 vaccine failed to elicit any of the
mmune responses seen in long-term nonprogressors of
IV infection, the immunization process was just as
rduous as other nonlive vaccines such as DNA vac-
ines (Barouch et al., 2000); recombinant vectors ex-
ressing HIV proteins (Robinson et al., 1999) and inacti-
ated viral virus particles (Murphey-Corb et al., 1989),
hat induced better immune responses, but which all
equired multiple injections of antigen, encompassing
everal months. Further, virus challenges in these stud-
es were applied only a few weeks following the last
accine boost. This led to our inquiry of whether a live
accine could be developed that would be safe, requiring
nly a single inoculation, and would confer long-term
FIG. 1. Replication of Vaccine-I, Vaccine-II, and pathogenic SHIVKU
stimulated with Con A for 2 days, washed, and inoculated with different
were added into each well of flat-bottom 96-well plates in 200 ml grow
Virus replication was monitored by determining RT activity in 100 m
xperiments.rotection against disease caused by pathogenic vi-
uses either homologous or distinctly heterologous to the
l
caccine virus. Two vaccine viruses were created (Joag et
l., 1998). The first was the initial virus received from the
odroski lab, SHIV-4, with the modification that both the
pu and nef genes were deleted from the construct. This
accine virus, DvpuDnefSHIV-4 (Vaccine-I), is similar to
ts parent and is strictly CD41 T-cell-tropic. It failed to
ause infection in macaques after oral inoculation and
as therefore given subcutaneously. Our second vac-
ine virus used the background of SHIV-4 but the env of
virus obtained from the spleen of one of the macaques
sed during the passaging of SHIV-4 (Joag et al., 1998).
he vpu was then deleted from the genome because this
ene was important in the eventual development of vir-
lence of SHIVKU that was isolated later in the passaging
experiment (Joag et al., 1996). This vaccine virus,
DvpuSHIVPPC (Vaccine-II), is dual tropic for CD4
1 T cells
nd macrophages (Fig. 1) and was inoculated orally into
acaques. Table 1 shows the relative replication effi-
iency of the two vaccine viruses compared to that of
HIVKU, the former two replicating productively for a
much shorter period, achieving much lower concentra-
tions, and, importantly, causing no pathological effects.
Twelve sexually mature macaques were inoculated;
six subcutaneously with Vaccine-I and six orally with
Vaccine-II. Both agents underwent transient productive
infection that was detectable in peripheral blood mono-
nuclear cells (PBMC), after which the agents could not
be isolated from PBMC or from lymph nodes. However,
DNA of the viruses persisted in lymph nodes. Seven
months after immunization, the animals were challenged
vaginally with SHIVKU. Four nonimmunized animals chal-
lenged similarly all developed typical high virus burdens
and rapid, subtotal loss of CD41 T cells within 3 weeks.
hree of these failed to mount any immune responses to
he challenge virus and they died with AIDS within 4
onths. The other did develop neutralizing antibody and
TLs to the virus, but the virus was always detectable in
caque PBMCs (A) and macrophage (B). The macaque PBMCs were
s at 104 TCID50/10
6 cells. The cells were washed after 2 h and 105 cells
ium. The supernatants were collected in triplicate on days indicated.
ernatant. The results described represent means 6 SD from threein ma
viruse
th medymph nodes. It succumbed to disease 18 months after
hallenge (Joag et al., 1998; Silverstein et al., 2000).
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3MINIREVIEWThe protection provided by Vaccine-I was similar to
that achieved naturally by the fourth control animal. All
six of the immunized animals became infected with the
challenge virus, although replication of the agent was
restricted to minimal levels for several months among
different animals. All six developed antibody and CTL
responses to the virus, but eventually the challenge virus
reappeared in the PBMC, accompanied by loss of CD41
T cells. Late-appearing viruses from two animals were
found to be immune-escape agents (Stipp et al., 2000).
Four of the six animals died with AIDS during a 2-year
period following challenge.
The six animals immunized with Vaccine-II have been
completely protected from disease for more than 3 years,
as indicated by continuous monitoring of the state of the
infection at 2-month intervals. All six animals had be-
come infected with the challenge virus as indicated by
PCR analysis of lymph node DNA. However, there was
minimal replication of the virus in PBMC of a few animals
during the first 18 weeks following challenge. No infec-
tion in these cells was detected again during the next 3
years. All six animals developed antibody and cellular
immune responses to the challenge virus, similar to the
animals in the Vaccine-I group. However, there was a
remarkable difference between the two groups in the
final outcome of the challenge experience. Vaccine viral
DNA persisted indefinitely in lymph nodes of all six
animals, even though the virus could only be rarely
isolated from these tissues. As mentioned above, DNA of
the challenge virus was also present in lymph nodes
during the first few months following challenge. How-
ever, this DNA became undetectable indefinitely, at dif-
ferent time periods in different animals (Silverstein et al.,
2000). At present, challenge virus DNA remains unde-
tectable in four of the six (Fig. 2). The virus could still be
isolated from the other two from rare cells in lymph
nodes, following depletion of CD81 T cells.
The experiment was repeated in eight animals that
ere first immunized with Vaccine-I and then Vaccine-II,
n an attempt to reduce the productive replication of the
T
Viral Load and Mean Replication Time of Attenua
Pathogenic SH
eak infectious cell number/106 PBMC 5500 6
Peak viral RNA load in plasma (copy Eq/ml) 3.5 3 108 6
Duration of virus replication (weeks) 27 6
a Values represent means 6 SE.
b ND, not done.
c Macaques supported the replication of pathogenic SHIVKU for the
d Both vaccine viruses replicated for the indicated time after which the
of the 2-year observation period.atter virus, following immunization with Vaccine-I. This
ffect was achieved (Kumar et al., 2001). Four of thenimals were challenged with heterologous pathogenic
HIV89.6P, kindly provided by Dr. N. Letvin, Harvard Med-
cal School, and four with homologous SHIVKU. The
former portion of the study has been reported (Kumar et
al., 2001). Similar to the foregoing study, replication of the
challenge viruses was inhibited and DNA of SHIV89.6P
ecame undetectable in two of the four by 18 months
ostchallenge (Fig. 3). This trend for possible gradual
limination of challenge virus in animals previously im-
unized with Vaccine-II has now been confirmed in
even other animals that were challenged 1 year follow-
ng immunization by rectal administration of a mixture of
hree pathogenic viruses, SHIVKU, SHIV89.6P, and
IVmac251. At 82 weeks postchallenge, DNA of SHIVKU has
become undetectable in one of the seven, SHIV89.6P in
IV Vaccines and Pathogenic SHIV in Macaques
5 6) Vaccine-I (n 5 10) Vaccine-II (n 5 12)
3.3 6 1.3 39.1 6 13
108 NDb 3.6 3 104 6 1 3 104
1.6 6 0.6d 4.6 6 0.5d
d time after which they succumbed to SHIV-induced AIDS.
tion was curtailed and the animals remained healthy for the remainder
FIG. 2. Persistence of vaccine and challenge virus DNA in PBMC and
lymph nodes of macaques immunized with Vaccine-II and challenged 7
months later with pathogenic SHIVKU. DNA from PBMCs and lymph
node cells were extracted at indicated time points. One-half microgram
of DNA from each sample was subjected to a nested PCR using
primers that distinguish between the full-length and truncated vpu
genes of the challenge and vaccine viruses, respectively. Five micro-
liters of PCR products was electrophoresed on a 2% agarose gel, and
DNA was visualized by ethidium bromide staining. Lanes are men-
tioned at the top of the upper-most panel and they remain in the sameABLE 1
ted SH
IVKU (n
2012a
2.73 3
1.3c
indicateorder throughout (Silverstein et al., 2000, reproduced with permission
from the Journal of Virology).
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4 MINIREVIEWfive of the seven, and SIVmac251 in six of the seven
acaques (Kumar et al., unpublished observation).
These data suggest strongly that effective immuniza-
tion against HIV may not be able to prevent infection with
the virus at the time of exposure to the agent. However,
it is possible to induce long-term responses that confer
protection against HIV disease after single administra-
tions of vaccine. The serendipitous finding that this pro-
tection can also lead to continuous reduction of chal-
lenge virus burdens in lymph nodes with the possibility
for elimination and cure of the infection adds to the value
of this live vaccine.
The mechanisms underlying the failure of Vaccine-I
and the remarkable success of Vaccine-II have not yet
been determined. However, preliminary studies suggest
that the immune responses induced by the two agents
were quantitative rather than qualitative and that they
may have differed in duration following immunization.
Similarly, we have no explanation why DNA of Vaccine-II
persisted indefinitely and why this was associated with
gradual elimination of the challenge virus. Nevertheless,
while the immunization with Vaccine-II virus indicated
the level of protection that can be achieved against HIV
infection and disease, it also highlights the tremendous
challenge that faces contemplated use of nonlive vac-
cines in the human population. Given the natural history
of HIV infection in which exposure can occur at random
times, a vaccine will only be successful if it can be
FIG. 3. Persistence of challenge virus DNA in four macaques that
were immunized sequentially with Vaccine-I followed by Vaccine-II and
challenged 7 months later with heterologous pathogenic SHIV89.6P.
NA from PBMCs and lymph node cells was extracted at indicated
ime points. One-half microgram of DNA from each sample was sub-
ected to a nested PCR using primers that amplify the envelope of
HIV89.6P but not the vaccine viruses. Five microliters of PCR products
was electrophoresed on a 2% agarose gel, and DNA was visualized by
ethidium bromide staining. Lanes are mentioned at the top of the
panels and remain in the same order throughout (Kumar et al., 2001).administered a minimum number of occasions rather
than the current mode of several injections applied overa period of several months. Further, the vaccine would
have to induce long-term cellular immunological re-
sponses that approximate those of LTNPs of HIV infec-
tion. At present, the only vaccine that comes close to
meeting these challenges is a vaccine similar to Vac-
cine-II described in this minireview.
ACKNOWLEDGMENTS
The work described in this report was supported by a Lied Basic
Science Grant from the University of Kansas Medical Center (A.K.) and
NIH Grants NS40238, RR13152, and RR06753 (O.N.).
REFERENCES
Barouch, D. H., Santra, S., Schmitz, J. E., Kuroda, M. J., Fu, T. M., Wagner,
W., Bilska, M., Craiu, A., Zheng, X. X., Krivulka, G. R., Beaudry, K.,
Lifton, M. A., Nickerson, C. E., Trigona, W. L., Punt, K., Freed, D. C.,
Guan, L., Dubey, S., Casimiro, D., Simon, A., Davies, M. E., Chastain,
M., Strom, T. B., Gelman, R. S., Montefiori, D. C., and Lewis, M. G.
(2000). Control of viremia and prevention of clinical AIDS in rhesus
monkeys by cytokine-augmented DNA vaccination. Science 290,
486–492.
Joag, S. V., Li, Z., Foresman, L., Stephens, E. B., Zhao, L. J., Adany, I.,
Pinson, D. M., McClure, H. M., and Narayan, O. (1996). Chimeric
simian/human immunodeficiency virus that causes progressive loss
of CD41 T cells and AIDS in pig-tailed macaques. J. Virol. 70,
3189–3197.
Joag, S. V., Li, Z., Wang, C., Jia, F., Foresman, L., Adany, I., Pinson, D. M.,
Stephens, E. B., and Narayan, O. (1998). Chimeric SHIV that causes
CD41 T cell loss and AIDS in rhesus macaques. J. Med. Primatol. 27,
59–64.
Joag, S. V., Liu, Z. Q., Stephens, E. B., Smith, M. S., Kumar, A., Li, Z.,
Wang, C., Sheffer, D., Jia, F., Foresman, L., Adany, I., Lifson, J.,
McClure, H. M., and Narayan, O. (1998). Oral immunization of ma-
caques with attenuated vaccine virus induces protection against
vaginally transmitted AIDS. J. Virol. 72, 9069–9078.
Kumar, A., Stipp, H. L., Sheffer, D., and Narayan, O. (1999). Use of
herpesvirus saimiri-immortalized macaque CD4(1) T cell clones as
stimulators and targets for assessment of CTL responses in ma-
caque/AIDS models. J. Immunol. Methods 230, 47–58.
Kumar, A., Lifson, J. D., Li, Z., Jia, F., Mukherjee, S., Adany, I., Liu, Z.,
Piatak, M., Sheffer, D., McClure, H. M., and Narayan, O. (2001).
Sequential immunization of macaques with two differentially attenu-
ated vaccines induced long-term virus-specific immune responses
and conferred protection against AIDS caused by heterologous sim-
ian human immunodeficiency virus (SHIV89.6P). Virology 279, 241–
256.
Kumar, A., Lifson, J. D., Silverstein, P. S., Jia, F., Sheffer, D., Li, Z., and
Narayan, O. (2000). Evaluation of immune responses induced by
HIV-1 gp120 in rhesus macaques: Effect of vaccination on challenge
with pathogenic strains of homologous and heterologous simian
human immunodeficiency viruses. Virology 274, 149–164.
McCormick-Davis, C., Zhao, L. J., Mukherjee, S., Leung, K., Sheffer, D.,
Joag, S. V., Narayan, O., and Stephens, E. B. (1998). Chronology of
genetic changes in the vpu, env, and nef genes of chimeric simian–
human immunodeficiency virus (strain HXB2) during acquisition of
virulence for pig-tailed macaques. Virology 248, 275–283.
Murphey-Corb, M., Martin, L. N., Davison-Fairburn, B., Montelaro, R. C.,
Miller, M., West, M., Ohkawa, S., Baskin, G. B., Zhang, J. Y., and
Putney, S. D. (1989). A formalin-inactivated whole SIV vaccine confers
protection in macaques. Science 246, 1293–1297.
Nathanson, N., Hirsch, V. M., and Mathieson, B. J. (1999). The role of
nonhuman primates in the development of an AIDS vaccine. AIDS
13(Suppl. A), S113–S120.
RS
S
S
5MINIREVIEWPantaleo, G., and Fauci, A. S. (1995). New concepts in the immuno-
pathogenesis of HIV infection. Annu. Rev. Immunol. 13, 487–512.
obinson, H. L., Montefiori, D. C., Johnson, R. P., Manson, K. H., Kalish,
M. L., Lifson, J. D., Rizvi, T. A., Lu, S., Hu, S. L., Mazzara, G. P., Panicali,
D. L., Herndon, J. G., Glickman, R., Candido, M. A., Lydy, S. L., Wyand,
M. S., and McClure, H. M. (1999). Neutralizing antibody-independent
containment of immunodeficiency virus challenges by DNA priming and
recombinant pox virus booster immunizations. Nat. Med. 5, 526–534.
ilverstein, P. S., Mackay, G. A., Mukherjee, S., Li, Z., Piatak, M., Lifson,
J. D., Narayan, O., and Kumar, A. (2000). Pathogenic simian/human
immunodeficiency virus SHIV(KU) inoculated into immunized ma-caques caused infection, but virus burdens progressively declined
with time. J. Virol. 74, 10489–10497.
tephens, E. B., Joag, S. V., Sheffer, D., Liu, Z. Q., Zhao, L., Mukherjee,
S., Foresman, L., Adany, I., Li, Z., Pinson, D., and Narayan, O. (1996).
Initial characterization of viral sequences from a SHIV-inoculated
pig-tailed macaque that developed AIDS. J. Med. Primatol. 25, 175–
185.
tipp, H. L., Kumar, A., and Narayan, O. (2000). Characterization of
immune escape viruses from a macaque immunized with live-virus
vaccine and challenged with pathogenic SHIVKU-1. AIDS Res. Hum.
Retroviruses 16, 1573–1580.
